StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
KPT.TO$12.29+0.82%
Fair $12.29+0.0%

KPT.TO

KP Tissue Inc.

Consumer Defensive / Household & Personal ProductsToronto

$12.29

+0.10 (+0.82%)

Fairly Valued+0.0%Fair Value $12.29Fund rank 28/100 · Data gapFallback financials|
SA 37/D
F-Score: 3/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF n/d · quality 50.0/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 50/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

37/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · KPT.TOLocal privado en este navegador · KP Tissue Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$123M

P/E

13.7x

↓

EV/EBITDA

N/A

•

ROE

12.2%

↑

Gross Margin

N/A

•

Debt/Equity

N/A

•
52-Week Range$12
$9$12

TradingView lightweight chart

KPT.TO price, volumen y niveles de valoración

Último $12.29Periodo -29.2%
Fair value: $12.29

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

—

Latest source

Provider fallback

Margin decomposition

Último año: revenue — · net income $8.5M · FCF —

2022-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

—— pts

FCF margin

—— pts
MetricTTM
2025
2024
2023
2022
Income Statement
Net Income$8.5M$8.5M$2.4M$-4.9M$-10.2M
EBITDA$-433000.00$-433000.00$-619000.00$-1.0M$-752000.00
EPS0.850.850.24-0.50-1.03
Balance Sheet
Current Ratio1.001.00———
Returns
ROE12.2%12.2%3.5%-7.2%-13.8%
Valuation
P/E13.6613.6633.96——
P/B1.761.761.171.301.36
Growth & Yield
EPS Growth254.2%254.2%148.0%51.5%—
Dividend Yield7.2%7.2%———

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

8.7%

razonable

EPS terminal req.

$1.09

Spread vs growth

245.5%

5Y implied EPS CAGR

9.2%

razonable

EPS terminal req.

$1.32

Spread vs growth

245.0%

10Y implied EPS CAGR

9.6%

razonable

EPS terminal req.

$2.13

Spread vs growth

244.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +44.8%

Total return

+44.8%

Start / end P/E

37.2x → 14.5x

EPS bridge

0.24 → 0.85

Residual

-155.4%

EPS growth+254.2%
Multiple rerating-61.1%
Dividend+7.2%
Residual / FX / buybacks / cross-term-155.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.